Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report

EML4-ALK fusions are targetable oncogenic drivers in a subset of advanced non-small cell lung cancer (NSCLC) patients that can benefit from selected ALK inhibitors. Precise detection of ALK fusions may yield critical information for selection of appropriate therapy and hence improve patient survival...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Yingying Zhu, Ran Jia, Yang W. Shao, Liuqing Zhu, Qiuxiang Ou, Man Yu, Xue Wu, Yanbei Zhang
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2020-07-01
Colecção:Frontiers in Oncology
Assuntos:
lung adenocarcinoma
ALK rearrangement
alectinib
liquid biopsy
brain metastases
Acesso em linha:https://www.frontiersin.org/article/10.3389/fonc.2020.01259/full
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados